Semaglutide for Obesity
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently using anti-obesity medications or certain diabetes medications (GLP1R agonists).
What data supports the effectiveness of the drug Semaglutide for obesity?
Is semaglutide safe for humans?
How is the drug Semaglutide unique for treating obesity?
Semaglutide is unique for treating obesity because it is a glucagon-like peptide-1 receptor agonist that can be administered once a week and has shown the largest weight loss of any obesity medication, with about 15% reduction in initial weight over 68 weeks, along with improvements in cardiovascular risk factors.24101112
What is the purpose of this trial?
This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
Research Team
Andres Acosta, MD, PhD
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for adults with obesity (BMI ≥30 kg/m2), possibly with controlled chronic conditions like hypertension. It's not for those who've had significant weight changes recently, are pregnant or planning to be, have a history of bariatric surgery, untreated severe psychiatric issues, substance or eating disorders, suicidal behavior, alcohol abuse problems, or are using anti-obesity drugs.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive semaglutide or placebo weekly for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Semaglutide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Phenomix Sciences
Collaborator